

Communication to Scottish Health Boards and AD&TCs from the Scottish Medicines Consortium (SMC) in regard to Syner-KINASE® on the 8th December 2006

Syner-KINASE® (urokinase):

"We have been advised that Syner-Med (PP) Ltd will launch Syner-KINASE® (urokinase) on Friday the 8th December 2006. This product was originally licenced for use before the inception of SMC and was widely used in hospitals. In 2000 the license holder, Serono Ltd, withdrew the product, not for clinical/safety issues but for commercial reasons. It is understood that hospitals have continued to import unlicensed urokinase since 2000. Syner-Medica Ltd a sister company of Syner-Med Pharmaceutical Products Ltd has recently received a Marketing Authorisation Licence for urokinase (Syner-KINASE®) which is indicated for the lysis of blood clots in the following conditions:

- thrombosed intravascular catheters and cannula that are blocked by fibrin clots.
- thromboembolic occlusive vascular disease such as deep vein thrombosis, pulmonary embolism, and peripheral vascular occlusion.

SMC has advised Syner-Med (PP) Ltd, who are appointed as sole United Kingdom distributors for Syner-KINASE® that as the original licence predates the inception of SMC it is outwith their remit and a submission is not required. Syner-Med (PP) Ltd is actively marketing urokinase (Syner-KINASE®). Their product provides a licensed alternative to unlicensed imported products and its use should be considered a local formulary decision."

Syner-Med given permission by SMC to release this statement on the 19th December 2006

